Paragon Biosciences Emalex Capital, Inc.

Businessfiled

Paragon Biosciences Emalex Capital, Inc. operates in Pharmaceuticals, based in CHICACO. Paragon is a global life science leader that creates, builds and funds innovative biology-based companies to treat and cure diseases.

Capital & rounds (filed)filed

Paragon Biosciences Emalex Capital, Inc. has raised $377M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).

Largest single filing: $270M on 2022-05-18.

Most recent recorded round closed around 2022-05-18.

Valuation (modeled)modeled

Provath models Paragon Biosciences Emalex Capital, Inc. at approximately $5.5B (range $1.3B–$9.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 2.85× the median modeled value of Series D+ Pharmaceuticals companies in 2022–2024 (18 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 6 months.

Last raise 4.1 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 99% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 99% of those peers.

Closest niche peers: TrialSpark, Inc., Fog Pharmaceuticals, Inc., MAPS Public Benefit Corp, Karyopharm Therapeutics Inc., ADARx Pharmaceuticals, Inc..

Peoplefiled

12 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.